| __timestamp | Apellis Pharmaceuticals, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 8379522 | 1271353000 |
| Thursday, January 1, 2015 | 13730311 | 1620577000 |
| Friday, January 1, 2016 | 22978599 | 2052295000 |
| Sunday, January 1, 2017 | 40303878 | 2075142000 |
| Monday, January 1, 2018 | 105285576 | 2186100000 |
| Tuesday, January 1, 2019 | 220968770 | 3036600000 |
| Wednesday, January 1, 2020 | 299921000 | 2735000000 |
| Friday, January 1, 2021 | 420869000 | 2908100000 |
| Saturday, January 1, 2022 | 387236000 | 3592500000 |
| Sunday, January 1, 2023 | 354387000 | 4439000000 |
| Monday, January 1, 2024 | 5132000000 |
Cracking the code
In the ever-evolving landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Regeneron Pharmaceuticals, Inc. and Apellis Pharmaceuticals, Inc. have demonstrated contrasting trajectories in their R&D investments.
Regeneron, a leader in the biopharma industry, has consistently increased its R&D expenses, peaking at approximately $4.4 billion in 2023. This represents a staggering 250% increase from 2014, underscoring its dedication to pioneering treatments. In contrast, Apellis, a relatively newer player, has shown a remarkable growth trajectory, with R&D expenses rising from $8 million in 2014 to $354 million in 2023, marking an impressive 4,100% increase.
These figures highlight the dynamic nature of the biopharma sector, where strategic investments in R&D can propel companies to the forefront of medical innovation.
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Alnylam Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. or TG Therapeutics, Inc.: Who Invests More in Innovation?
R&D Spending Showdown: Regeneron Pharmaceuticals, Inc. vs Viking Therapeutics, Inc.
Breaking Down SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.
Comparing Innovation Spending: Regeneron Pharmaceuticals, Inc. and ImmunityBio, Inc.
Regeneron Pharmaceuticals, Inc. or Arrowhead Pharmaceuticals, Inc.: Who Invests More in Innovation?
R&D Insights: How Regeneron Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. Allocate Funds
argenx SE vs Apellis Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: Dr. Reddy's Laboratories Limited vs Apellis Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Ascendis Pharma A/S vs Apellis Pharmaceuticals, Inc.
Research and Development Investment: Alpine Immune Sciences, Inc. vs Apellis Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Apellis Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.